Literature DB >> 19082791

The characteristic change in the distribution of S-100 immunoreactive folliculostellate cells in rat anterior pituitary upon long-term estrogen treatment is prevented by concomitant progesterone treatment.

Andrea Heinzlmann1, Katalin Köves.   

Abstract

The presence of folliculostellate cells in the anterior pituitary was described 49 years ago. These cells give about 10% of the whole cell population and through their long processes they provide intrahypophyseal communication. The folliculostellate cells contain S-100 protein. Its immunostaining was used to identify these cells. It was previously found that the diethylstilbestrol treatment basically influences the morphology and function of the trophic hormone secreting as well as the folliculostellate cells. In the present experiment, we have studied whether a concomitant progesterone treatment can prevent or attenuate changes caused by diethylstilbestrol treatment in the distribution of folliculostellate, prolactin, and GH cells. Diethylstilbestrol alone induced the appearance of prolactinomas. Inside the prolactinomas, folliculostellate cells were scattered but outside the prolactinomas they formed a demarcation line. Inside the prolactinomas, there were only a few growth hormone immunoreactive cells but they surrounded the prolactinomas in a ring-like pattern. When diethylstilbestrol was implanted with progesterone, the changes being characteristic for diethylstilbestrol treatment, could not develop. Concomitant progesterone influence prevented morphological changes in the anterior pituitary. Progesterone alone had no effect. In accordance with the formation of prolactinomas, the plasma prolactin level was very high in diethylstilbestrol treated rats. Concomitant progesterone treatment prevented the effect of diethylstilbestrol. Progesterone alone did not influence the prolactin level. GH levels did not significantly differ in any groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082791     DOI: 10.1007/s12020-008-9096-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

2.  Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells.

Authors:  N Ferrara; D W Leung; G Cachianes; J Winer; W J Henzel
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Follistatin gene expression in the pituitary: localization in gonadotropes and folliculostellate cells in diestrous rats.

Authors:  U B Kaiser; B L Lee; R S Carroll; G Unabia; W W Chin; G V Childs
Journal:  Endocrinology       Date:  1992-05       Impact factor: 4.736

4.  Differentiation of isolated chromophobes into acidophils or basophils when transplanted into the hypophysiotrophic area of hypothalamus.

Authors:  F Yoshimura; K Harumiya; H Ishikawa; Y Otsuka
Journal:  Endocrinol Jpn       Date:  1969-10

5.  Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons.

Authors:  J E DeMaria; J D Livingstone; M E Freeman
Journal:  Brain Res       Date:  2000-10-06       Impact factor: 3.252

6.  Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.

Authors:  I Shimon; D R Hinton; M H Weiss; S Melmed
Journal:  Clin Endocrinol (Oxf)       Date:  1998-01       Impact factor: 3.478

7.  Progestins modulate the action of estrogen on gonadotropin-releasing hormone, luteinizing hormone and prolactin in the rat.

Authors:  A R Genazzani; F Petraglia; M Silferi; A M Lattesa; G Coukos; A D Genazzani; P Artini; C Nappi; A Volpe
Journal:  Gynecol Obstet Invest       Date:  1990       Impact factor: 2.031

8.  Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors.

Authors:  B Caronti; G Palladini; M G Bevilacqua; E Petrangeli; B Fraioli; G Cantore; G Tamburrano; C M Carapella; M L Jaffrain-Rea
Journal:  Tumour Biol       Date:  1993

9.  Effects of progesterone administration on follicle-stimulating hormone and prolactin release in estrogen treated eugonadal adult men.

Authors:  A Mancini; L De Marinis; C Fiumara; A Saporosi; M L Fabrizi; E Menini; P Turchi; G F Menchini-Fabris
Journal:  Andrologia       Date:  1991 Sep-Oct       Impact factor: 2.775

10.  Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors.

Authors:  K A Elias; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

View more
  4 in total

1.  Effect of concomitant progesterone administration or the effect of removal of estrogen capsule on changes caused by long-term estrogen treatment in pituitary VIP immunoreactivities.

Authors:  Andrea Heinzlmann; Katalin Köves; György M Nagy
Journal:  Endocrine       Date:  2010-03-30       Impact factor: 3.633

2.  Testing the Critical Window Hypothesis of Timing and Duration of Estradiol Treatment on Hypothalamic Gene Networks in Reproductively Mature and Aging Female Rats.

Authors:  Weiling Yin; Sean M Maguire; Brian Pham; Alexandra N Garcia; Nguyen-Vy Dang; Jingya Liang; Andrew Wolfe; Hans A Hofmann; Andrea C Gore
Journal:  Endocrinology       Date:  2015-05-27       Impact factor: 4.736

3.  Sexual dimorphism in the effect of concomitant progesterone administration on changes caused by long-term estrogen treatment in pituitary hormone immunoreactivities of rats.

Authors:  Andrea Heinzlmann; Katalin Koves; Magdolna Kovacs; Valer Csernus
Journal:  Med Sci Monit       Date:  2011-02-25

4.  Cell Type- and Sex-Dependent Transcriptome Profiles of Rat Anterior Pituitary Cells.

Authors:  Patrick A Fletcher; Kosara Smiljanic; Rafael Maso Prévide; James R Iben; Tianwei Li; Milos B Rokic; Arthur Sherman; Steven L Coon; Stanko S Stojilkovic
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-18       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.